Innoviva, Inc. (INVA) Dividend History

Innoviva, Inc. is a biotechnology company focused on the development and commercialization of respiratory and other specialty healthcare products. It primarily licenses its portfolio of pharmaceutical products and intellectual property to partner companies, with a strong emphasis on inhaled therapeutics for conditions like asthma and COPD. The company leverages its expertise in respiratory medicine to generate royalty revenue and support its strategic growth initiatives.

1350 Old Bayshore Highway, Burlingame, CA, 94010
Phone: (650) 238-9600
Website:

Dividend History

Pay Date Amount Ex Dividend Date Record Date
September 30, 2015 $0.25 09/08/2015 09/10/2015
June 30, 2015 $0.25 06/10/2015 06/12/2015
March 31, 2015 $0.25 03/10/2015 03/12/2015
December 23, 2014 $0.25 11/21/2014 11/25/2014
September 18, 2014 $0.25 08/26/2014 08/28/2014

Dividends Summary

  • Innoviva, Inc. has issued 5 dividends over a period of about a year
  • The most recent dividend was paid 3539 days ago, on September 30, 2015
  • The first recorded dividend was paid on September 18, 2014
  • The highest dividend payout was $0.25 per share
  • The average dividend over this 1 year span is $0.25 per share

Company News

  • Basilea Pharmaceutica Ltd has entered into an exclusive distribution and license agreement with Innoviva Specialty Therapeutics, Inc. for the commercialization of Basilea's hospital anti-MRSA antibiotic Zevtera® (ceftobiprole) in the United States.

    GlobeNewswire Inc.
  • Cantor Fitzgerald has initiated coverage on Innoviva, Inc. (NASDAQ:INVA), citing the company’s unique business model centered around royalties and healthcare assets. The company receives royalties from GSK plc (NYSE:GSK) for popular asthma and COPD products, including Relvar/Breo and Anoro, with combined sales of over $2 billion in 2023. “We believe their manufacturing complexity provides further protection from potential competitors,” Cantor analyst writes. Cantor projects around $1.1 billion of 5-year projected royalty revenues from GSK and initiates Innoviva with an Overweight rating. The analyst says Breo and Anoro have exceeded expectations, even during challenging times such as the COVID-19 ...Full story available on Benzinga.com

    Benzinga
  • High-quality stocks can do well when prices are rising or falling. Here’s why.

    MarketWatch
    Featured Companies: AM CW CXW HCC OTTR PCAR RDN SLM TNC
  • The Food and Drug Administration said Tuesday that it approved Innoviva's Xacduro pneumonia treatment, which fights the Acinetobacter bacteria.

    MarketWatch
  • Although US stocks closed higher on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. DISH Network The Trade: DISH Network Corporation (NASDAQ: DISH) Director James Defranco acquired a total 3,000,000 shares an average price of ...

    Benzinga
    Featured Companies: MGTX OXY
Dividend data last updated 06/08/2025 01:51:32 UTC